Continuous intravenous infusion of lorazepam as seizure prophylaxis in children treated with high-dose busulfan

Bone Marrow Transplantation

Volumn 42, Issue 2, 2008, Pages 135-136

  Caselli, D ^a   Ziino, O ^b   Bartoli, A ^c   Santangelo, G ^b   Vanadia, F ^b   Arico M ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Ospedale dei Bambini G Di Cristina   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; LORAZEPAM; MELPHALAN;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; CHILD; CHILD CARE; CLINICAL ARTICLE; CONTINUOUS INFUSION; DROWSINESS; DRUG BLOOD LEVEL; DRUG MEGADOSE; EWING SARCOMA; GRAFT REJECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LETTER; NAUSEA; NEUROBLASTOMA; PRIORITY JOURNAL; SEIZURE; SEVERE COMBINED IMMUNODEFICIENCY; VOMITING; WITHDRAWAL SYNDROME;

ADOLESCENT; ANTICONVULSANTS; BUSULFAN; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; INFUSIONS, INTRAVENOUS; LORAZEPAM; SEIZURES; TRANSPLANTATION CONDITIONING;

EID: 48349135648     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.91     Document Type: Letter

References (9)

1. Vassal G, Deroussent A, Hartmann O, Challine D, Benhamou E, Valteau-Couanet D et al. Dose-dependent neurotoxicity of high-dose busulfan in children: A clinical and pharmacological study. Cancer Res 1990; 50: 6203-6207.
2. Hassan M, Oberg G, Björkholm M, Wallin I, Lindgren M. Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. Cancer Chemother Pharmacol 1993; 33: 181-186.
3. Chan KW, Mullen CA, Worth LL, Choroszy M, Koontz S, Tran H et al. Lorazepam for seizure prophylaxis during high-dose busulfan administration. Bone Marrow Transplant 2002; 29: 963-965.
4. Treiman DM, Meyers PD, Walton NY, Collins JF, Colling C, Rowan AJ et al. A comparison of four treatments for generalized convulsive status epilepticus. Veterans affairs status epilepticus cooperative study group. N Engl J Med 1998; 339: 792-798.
5. Greenblatt DJ, von Moltke LL, Ehrenberg BL, Harmatz JS, Corbett KE, Wallace DW et al. Kinetics and dynamics of lorazepam during and after continuous intravenous infusion. Crit Care Med 2000; 28 2750-2757.
6. Dominguez KD, Crowley MR, Coleman DM, Katz RW, Wilkins DG, Kelly HW. Withdrawal from lorazepam in critically ill children. Ann Pharmacother 2006; 40: 1035-1039.
7. Henner WD, Furlong EA, Flaherty MD, Shea TC, Peters WP. Measurement of busulfan in plasma by high-performance liquid chromatography. J Chromatogr 1987; 416: 426-432.
8. Tran HT, Madden T, Petropoulos D, Worth LL, Felix EA, Sprigg-Saenz HA et al. Individualizing high-dose oral busulfan: Prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies. Bone Marrow Transplant 2000; 26: 463-470.
9. Zwaveling J, Bredius RG, Cremers SC, Ball LM, Lankester AC, Teepe-Twiss IM et al. Intravenous busulfan in children prior to stem cell transplantation: Study of pharmacokinetics in association with early clinical outcome and toxicity. Bone Marrow Transplant 2005; 35 17-23.